UK Government Announces £1 Million Investment in GARDP to Address Drug-Resistant Infections

3 Jun 2021

The Global Antibiotic Research and Development Partnership (GARDP) and the Global Antimicrobial Resistance Innovation Fund (GAMRIF), part of the UK Department of Health and Social Care, are pleased to announce £1 million of funding to support GARDP’s efforts to develop treatments for the drug-resistant infections that pose the greatest threat to global health. The funding comes on top of £13 million previously committed by the UK government to GARDP.

The new investment represents a contribution to all GARDP programmes, including to the development of SECURE, a new antibiotics access initiative co-developed by GARDP and the World Health Organization (WHO) in collaboration with other international bodies. SECURE’s mission is to expand access to essential antibiotics to prepare countries for the silent pandemic of drug-resistant bacterial infections. These essential antibiotics will include new antibiotics to combat drug-resistant infections, but also existing antibiotics that are not widely available or suffer from frequent supply chain interruptions and shortages.

“The UK is committed to tackling antimicrobial resistance, one of the biggest threats to global health, and is a key focus of our G7 Presidency. Our additional funding will continue to support the fantastic work of GARDP in the development of vital treatments to treat drug-resistant infections. This will help safeguard the future of modern medicine,” said Lord Bethell, UK Minister for Innovation.

Seamus O’Brien, GARDP Director of Research and Development, said: “We are extremely pleased by the UK’s increased contribution at a time when COVID-19 has demonstrated the critical importance of preventing and preparing for pandemics, including the pandemic of drug-resistant infections. By investing an additional £1 million, the UK is again demonstrating leadership in efforts to accelerate the development and delivery of life-changing and lifesaving antibiotics for every person who needs them.”

With the UK’s 2021 G7 Presidency prioritising global health threats, this funding recognizes that effective antibiotics underpin modern healthcare, and reinforces the partnership between the UK and GARDP in ensuring that such antibiotics are available now and for future generations. Funding both GARDP’s pipeline and the development of SECURE reflects the shared belief of GARDP and GAMRIF that developing new treatments and ensuring responsible access for all in need are inseparable.

The unchecked growth of drug-resistant infections has long-term implications. Resistant infections kill an estimated 700,000 people a year, a number projected to increase exponentially as drug resistance grows and imperils our ability to treat even common infections. The consequences of not addressing the silent pandemic of drug-resistant infections now could result in a future where we are unable to treat common infections such as pneumonia, urinary tract infections and infections in newborns.

About the Global AMR Innovation Fund (GAMRIF)

The Department for Health and Social Care (DHSC) is the UK Government department which is responsible for helping people to live more independent, healthier lives for longer. The partnership with GARDP is part of DHSC’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF was established to provide seed funding for innovative research and development, specifically in neglected and underinvested areas, in the field of AMR. GAMRIF is a £50m UK Aid investment, which means all projects funded must support research primarily and directly for the benefit of people in low- and middle-income countries (LMICs). The Fund takes a ‘One Health’ approach, seeking to invest in potential solutions to reduce the threat of AMR in humans, animals, fish and the environment. The Fund seeks to leverage additional global funding through interaction with international government bodies, public-private partnerships, product development partnerships, global funding mechanisms and global fora.


The Global Antibiotic Research and Development Partnership (GARDP) is a Swiss not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP was created by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment. We aim to develop five new treatments by 2025 to fight drug-resistant infections. GARDP is funded by the governments of Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom, as well as Médecins Sans Frontières and private foundations. GARDP is registered under the legal name GARDP Foundation.

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.